Sponsor or institution
Clinical trials and research at Hangzhou Converd Co., Ltd.
As of November 12, 2026, Find a Trial lists 2 clinical trials run by Hangzhou Converd Co., Ltd. that are recruiting, in China. By phase: Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Oncolytic vaccinia virus (hV01) plus PD-1 drug tislelizumab for advanced solid tumors
This trial will test whether adding an IL-21–expressing oncolytic vaccinia virus (hV01) to the PD‑1 drug tislelizumab is safe and can shrink tumors in adults with advanced solid cancers that no longer respond to standard treatments.
-
hV01 (IL-21–expressing oncolytic vaccinia) for advanced pancreatic cancer
This trial tests whether injections of hV01, a vaccinia virus engineered to deliver IL‑21, can help people with advanced pancreatic cancer whose tumors can be injected.
Quick answers
How many clinical trials run by Hangzhou Converd Co., Ltd. are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.